论文部分内容阅读
目的研究NM23基因与儿童恶性肿瘤分期、分化及转移的关系，为肿瘤的预后判断提供依据。方法应用免疫组织化学技术检测18例肾母细胞瘤和11例神经母细胞瘤中NM23－H1蛋白的表达情况。结果18例肾母细胞瘤中，NM23H1蛋白阳性者11例，阳性率61．1％，I、II期及无转移组明显高于Ⅲ、Ⅳ期及转移组，而与预后结构型无关。11例神经母细胞瘤中，NM23－H1蛋白阳性者6例，阳性宰54．5％，无转移组显著高于转移组，而与分期无关。结论在肾母细胞瘤和神经母细胞瘤中NM23－H1蛋白阳性表达与肿瘤转移抑制正相关，与肾母细胞瘤分期负相关；NM23可以作为判定肾母细胞瘤和神经母细胞瘤预后的一项指标；联合检测NM23－H1和P53蛋白，对于判断肿瘤分化及预后更有意义。
Objective To study the relationship between NM23 gene and staging, differentiation and metastasis of childhood malignant tumors and to provide evidence for the prognosis of the tumors. Methods Immunohistochemistry was used to detect the expression of NM23-H1 protein in 18 cases of nephroblastoma and 11 cases of neuroblastoma. Results Among the 18 cases of nephroblastoma, 11 cases were positive for NM23H1 protein, the positive rate was 61.1%. The positive rate of NM23H1 protein in stage I, II and metastasis was significantly higher than that in stage III and IV, but not with the prognosis. Among the 11 cases of neuroblastoma, 6 cases were positive for NM23-H1 protein, 54.5% positive for the NM23-H1 protein. There was no correlation between the NM23-H1 protein expression and the metastasis group in metastasis group. Conclusions The positive expression of NM23-H1 protein in nephroblastoma and neuroblastoma is positively correlated with the inhibition of tumor metastasis and negatively correlated with the stage of nephroblastoma. NM23 can be used as a marker for prognosis of nephroblastoma and neuroblastoma Item index; joint detection of NM23-H1 and P53 protein, for the judgment of tumor differentiation and prognosis more meaningful.